SUPAC-IR guidance does not eliminate site inspection requirements, FDA reminds industry.
This article was originally published in The Tan Sheet
Executive Summary
SUPAC-IR GUIDANCE DOES NOT ELIMINATE SITE CHANGE INSPECTIONS, FDA emphasizes in an April 11 letter to industry on the agency's implemen-tation of its guidance on Scale-Up and Post-Approval Changes for Immediate Release Solid Oral Dosage Forms. The guidance, finalized in November, "does not eliminate inspection requirements for site changes, nor requirements that firms have adequate process validation to support all changes," the letter states.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning